-
Je něco špatně v tomto záznamu ?
Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3
V. Heine, M. Hovorková, M. Vlachová, M. Filipová, L. Bumba, O. Janoušková, M. Hubálek, J. Cvačka, L. Petrásková, H. Pelantová, V. Křen, L. Elling, P. Bojarová
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- biomimetické materiály chemická syntéza chemie farmakologie MeSH
- galektiny antagonisté a inhibitory genetika metabolismus MeSH
- glykoproteiny chemie metabolismus MeSH
- kinetika MeSH
- krevní proteiny antagonisté a inhibitory genetika metabolismus MeSH
- lidé MeSH
- molekulární struktura MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Galectin-3 plays a crucial role in cancerogenesis; its targeting is a prospective pathway in cancer diagnostics and therapy. Multivalent presentation of glycans was shown to strongly increase the affinity of glycoconjugates to galectin-3. Further strengthening of interaction with galectin-3 may be accomplished using artificial glycomimetics with apt aryl substitutions. We established a new, as yet undescribed chemoenzymatic method to produce selective C-3-substituted N,N'-diacetyllactosamine glycomimetics and coupled them to human serum albumin. From a library of enzymes, only β-N-acetylhexosaminidase from Talaromyces flavus was able to efficiently synthesize the C-3-propargylated disaccharide. Various aryl residues were attached to the functionalized N,N'-diacetyllactosamine via click chemistry to assess the impact of the aromatic substitution. In ELISA-type assays with galectin-3, free glycomimetics exhibited up to 43-fold stronger inhibitory potency to Gal-3 than the lactose standard. Coupling to human serum albumin afforded multivalent neo-glycoproteins with up to 4209-fold increased inhibitory potency per glycan compared to the monovalent lactose standard. Surface plasmon resonance brought further information on the kinetics of galectin-3 inhibition. The potential of prepared neo-glycoproteins to target galectin-3 was demonstrated on colorectal adenocarcinoma DLD-1 cells. We investigated the uptake of neo-glycoproteins into cells and observed limited non-specific transport into the cytoplasm. Therefore, neo-glycoproteins primarily act as efficient scavengers of exogenous galectin-3 of cancer cells, inhibiting its interaction with the cell surface, and protecting T-lymphocytes against galectin-3-induced apoptosis. The present neo-glycoproteins combine the advantage of a straightforward synthesis, selectivity, non-toxicity, and high efficiency for targeting exogenous galectin-3, with possible application in the immunomodulatory treatment of galectin-3-overexpressing cancers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025156
- 003
- CZ-PrNML
- 005
- 20211026134055.0
- 007
- ta
- 008
- 211013s2021 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2021.113500 $2 doi
- 035 __
- $a (PubMed)33962190
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Heine, Viktoria $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic; Institute of Biotechnology and Helmholtz Institute for Biomedical Engineering, RWTH Aachen, Pauwelstr. 20, D-52079 Aachen, Germany
- 245 10
- $a Immunoprotective neo-glycoproteins: Chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3 / $c V. Heine, M. Hovorková, M. Vlachová, M. Filipová, L. Bumba, O. Janoušková, M. Hubálek, J. Cvačka, L. Petrásková, H. Pelantová, V. Křen, L. Elling, P. Bojarová
- 520 9_
- $a Galectin-3 plays a crucial role in cancerogenesis; its targeting is a prospective pathway in cancer diagnostics and therapy. Multivalent presentation of glycans was shown to strongly increase the affinity of glycoconjugates to galectin-3. Further strengthening of interaction with galectin-3 may be accomplished using artificial glycomimetics with apt aryl substitutions. We established a new, as yet undescribed chemoenzymatic method to produce selective C-3-substituted N,N'-diacetyllactosamine glycomimetics and coupled them to human serum albumin. From a library of enzymes, only β-N-acetylhexosaminidase from Talaromyces flavus was able to efficiently synthesize the C-3-propargylated disaccharide. Various aryl residues were attached to the functionalized N,N'-diacetyllactosamine via click chemistry to assess the impact of the aromatic substitution. In ELISA-type assays with galectin-3, free glycomimetics exhibited up to 43-fold stronger inhibitory potency to Gal-3 than the lactose standard. Coupling to human serum albumin afforded multivalent neo-glycoproteins with up to 4209-fold increased inhibitory potency per glycan compared to the monovalent lactose standard. Surface plasmon resonance brought further information on the kinetics of galectin-3 inhibition. The potential of prepared neo-glycoproteins to target galectin-3 was demonstrated on colorectal adenocarcinoma DLD-1 cells. We investigated the uptake of neo-glycoproteins into cells and observed limited non-specific transport into the cytoplasm. Therefore, neo-glycoproteins primarily act as efficient scavengers of exogenous galectin-3 of cancer cells, inhibiting its interaction with the cell surface, and protecting T-lymphocytes against galectin-3-induced apoptosis. The present neo-glycoproteins combine the advantage of a straightforward synthesis, selectivity, non-toxicity, and high efficiency for targeting exogenous galectin-3, with possible application in the immunomodulatory treatment of galectin-3-overexpressing cancers.
- 650 _2
- $a biomimetické materiály $x chemická syntéza $x chemie $x farmakologie $7 D040761
- 650 _2
- $a krevní proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D001798
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a galektiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D037161
- 650 _2
- $a glykoproteiny $x chemie $x metabolismus $7 D006023
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hovorková, Michaela $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, CZ-12843, Prague 2, Czech Republic
- 700 1_
- $a Vlachová, Miluše $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
- 700 1_
- $a Filipová, Marcela $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského Nám. 2, CZ-16206 Prague 6, Czech Republic
- 700 1_
- $a Bumba, Ladislav $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
- 700 1_
- $a Janoušková, Olga $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského Nám. 2, CZ-16206 Prague 6, Czech Republic
- 700 1_
- $a Hubálek, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Náměstí 2, CZ-16610 Prague 6, Czech Republic
- 700 1_
- $a Cvačka, Josef $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Náměstí 2, CZ-16610 Prague 6, Czech Republic
- 700 1_
- $a Petrásková, Lucie $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
- 700 1_
- $a Pelantová, Helena $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
- 700 1_
- $a Křen, Vladimír $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic
- 700 1_
- $a Elling, Lothar $u Institute of Biotechnology and Helmholtz Institute for Biomedical Engineering, RWTH Aachen, Pauwelstr. 20, D-52079 Aachen, Germany
- 700 1_
- $a Bojarová, Pavla $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-14220, Prague 4, Czech Republic. Electronic address: bojarova@biomed.cas.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 220, č. - (2021), s. 113500
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33962190 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134101 $b ABA008
- 999 __
- $a ok $b bmc $g 1714277 $s 1145663
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 220 $c - $d 113500 $e 20210427 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20211013